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This year’s Albert Lasker Basic Medical Research Award goes to John Gurdon and Shinya 
Yamanaka for their contributions to our understanding of how to reprogram adult cells back to 
early embryonic states.Understanding how to reprogram adult 
cells to the pluripotent state opens up 
new horizons in human biology, provides 
new tools to study disease, and indicates 
the route to future personalized stem cell 
therapy. The research by John Gurdon of 
the Gurdon Institute, Cambridge, UK and 
Shinya Yamanaka of Kyoto University, 
Japan that has led to successful repro-
gramming of adult cells to the pluripo-
tent state earns them this year’s Albert 
Lasker Basic Medical Research Award. 
The contributions of the two awardees 
are very different in kind and in timelines, 
but together they have changed the way 
we think about the stability of the differ-
entiated cell state. John Gurdon is recog-
nized for his lifelong endeavor to under-
stand the process by which an adult cell 
nucleus can be reprogrammed to start 
development all over again when trans-
planted into an egg. Shinya Yamanaka, 
on the other hand, has leapt into promi-
nence in very short order, with a series of 
experiments beginning in 2006 showing 
that adult cells can be reprogrammed to 
pluripotency directly by added expres-
sion of just four key transcription factors, 
generating so-called induced pluripotent 
stem (iPS) cells. The joint award is a sat-
isfying way of recognizing that every new 
breakthrough depends on the cumula-
tive knowledge generated over years of 
research—“standing on the shoulders of 
giants.”
The discoveries of nuclear transfer 
reprogramming by Gurdon and induced 
pluripotent stem cells by Yamanaka both 
challenged the underlying paradigms of 
developmental biology in important ways 
and so were of immediate impact in the 
scientific community. But both discov-eries also took place in the glare of the 
media because of their association with 
the controversial issues of cloning and 
the derivation of pluripotent cells from 
human embryos. Indeed, Yamanaka’s 
discovery of iPS cells, apart from being 
great science, has been remarkable for 
the way in which it has transformed the 
public debate on the ethics of stem cell 
research. Although the media and the 
public may continue to focus on the ethi-
cal controversies, the Lasker prize and 
this Essay focus on the importance of 
the underlying science, which is of the 
highest order.
From Frogs to Dolly
John Gurdon is one of the major figures 
in modern vertebrate developmental 
biology, whose scientific contributions, 
scholarly works, and science leader-
ship have inspired the careers of many 
(including the author of this Essay) and 
shaped our understanding of early 
embryo development and gene regula-
tion. Famously, Gurdon was not consid-
ered a strong science student in school. 
His report card at Eton read: “I believe 
Gurdon has ideas about becoming a 
scientist: on his present showing this is 
quite ridiculous: if he can’t learn simple 
biological facts …. it would be a sheer 
waste of time, both on his part and of 
those who would have to teach him” 
(Gurdon, 2006). But when we examine 
Gurdon’s career we see why the teacher 
was upset. John is driven by curiosity, 
always asks clear and interesting ques-
tions, and strives to make sense of the 
answers. The kind of science teaching 
that is still too prevalent in our schools, 
in which science is considered as a set Cell 138, Seof facts that need to be learned by rote, 
is the complete antithesis of Gurdon’s 
approach. A case study of Gurdon’s 
career, in which he always asked appar-
ently simple questions and devised 
apparently simple experiments to test 
them, would help our science educators 
understand how to engage students in 
the excitement and fun of science dis-
covery.
The simple question that led Gur-
don to his major discoveries in nuclear 
transfer was: “is the genome irreversibly 
altered as cells become more special-
ized during development?” In the 1960s, 
it was already clear that the program of 
development relied on differential gene 
expression leading to apparently irre-
versible specialization of cells. What 
was unclear was how this stability of 
the differentiated state could be main-
tained without underlying changes in 
the genome. Barbara McClintock had 
shown that mobile elements could 
“jump” around the genome and change 
gene transcription, so could develop-
ment involve DNA changes that perma-
nently turned genes on or off? Gurdon 
realized that the best way to test whether 
the genome was intact in a specialized 
cell was to take that genome back to 
the beginning of development and ask 
whether it retained the capacity to drive 
normal development. He knew of the 
experiments of Briggs and King in 1952 
in the frog Rana pipiens, in which they 
had transplanted blastula nuclei into 
enucleated eggs and produced viable 
tadpoles. However, when they repeated 
the experiments with nuclei from later 
endoderm cells, development was very 
limited. Briggs and King interpreted their ptember 18, 2009 ©2009 Elsevier Inc. 1047
results as suggesting that there was 
some form of irreversible nuclear change 
associated with the differentiated state.
Gurdon extended these early experi-
ments in a series of seminal studies 
beginning in the late 1950s, using the 
African clawed toad, Xenopus laevis, 
which had become and continues to be 
the amphibian most used in laboratory 
studies. Using nuclei carrying a ribo-
somal RNA gene deletion as a marker, 
he was able to generate live frogs from 
transplanted neurula stage endoderm 
(Gurdon, 1962a). When he moved on to 
more differentiated cells, the success 
rate of producing normal development 
went down considerably. However, dif-
ferentiated brush border intestinal nuclei 
from feeding tadpoles could result in 
fertile adult frogs after nuclear transfer 
(Gurdon, 1962b). Gurdon interpreted 
these rare successes as clear evidence 
that cell differentiation did not involve 
permanent changes to the genome, and 
the many abnormal embryos as rep-
resenting failures in the correct repro-
gramming of the nuclei by the cytoplasm 
of the egg. Naysayers persisted, and 
Gurdon and colleagues continued to 
pursue the question of whether a truly 
differentiated adult cell nucleus could 
successfully be reprogrammed by the 
egg cytoplasm. Their most successful 
experiments in the 1970s showed that 
adult keratin-expressing skin cells could 
donate nuclei that would result in feed-
ing tadpole stages of development, after 
serial nuclear transfer (Gurdon, 2006).
Even in the early days of nuclear 
transfer experiments in frogs, journal-
ists rapidly extrapolated from frogs 
to humans and the ethical furore over 
human cloning began. Books and mov-
ies (e.g., The Boys from Brazil) took sci-
ence fact and made science fiction. Of 
course, this media attention was nothing 
to the media storm in 1996 that accom-
panied the birth of Dolly the sheep, the 
first mammal cloned by somatic cell 
nuclear transfer (SCNT) from an adult 
cell donor. Since the birth of Dolly, viable 
nuclear transfer-derived offspring have 
been made in many different mammalian 
species, although notably not yet in pri-
mates. In mice it has been conclusively 
shown that a nucleus from a highly spe-
cialized cell, such as a lymphocyte or an 
olfactory epithelial cell, can generate via-1048 Cell 138, September 18, 2009 ©2009 Eble cloned offspring. Why did it take so 
long for success in frogs to translate into 
success in mammals? Success rates 
for nuclear transfer in mammals are low, 
usually no more than 1% to 3% at best 
and, as with frogs, the success rate rap-
idly declines when adult nuclei are used 
instead of early embryonic nuclei. Many 
groups began experiments but gave up 
when faced with the formidable numbers 
of eggs and embryos needed to see 
success. Probably the reason why the 
first cloned mammal was a sheep rather 
than a mouse was because the potential 
commercial benefit of genetically manip-
ulating domestic animals maintained 
research interest in a difficult field.
The success of nuclear transfer not 
only demonstrated nuclear totipotency 
but also showed that the egg cyto-
plasm must be able to reshape the 
epigenetic environment of the nucleus 
to allow the entire program of develop-
ment to be reset. John Gurdon has con-
tinued through the rest of his career to 
be fascinated by this problem and, like 
all good problems, he has been able to 
return to it at intervals when new tools 
and techniques arise. While Professor 
of Embryology at Oxford, he provided 
early evidence that major changes in 
chromatin structure are one of the first 
events that occur. At this time also, he 
began a series of studies on the behav-
ior of nucleic acid macromolecules 
when injected into Xenopus eggs or 
oocytes, in the hope of providing a sim-
pler system to study reprogramming. He 
showed that DNA could be replicated 
after injection into eggs and that mRNA 
was translated after injection into eggs 
or oocytes—fundamental studies that 
continue to resonate today. Egg extracts 
have been used to study DNA replication 
in vitro, and mRNA injection into oocytes 
has been used as a “living test-tube” to 
identify receptors for neurotransmitters, 
ion channel genes, etc.
Gurdon moved from Oxford to the 
MRC Laboratory of Molecular Biology in 
Cambridge in 1971 and became Direc-
tor of the Wellcome Trust/CRC Institute 
in 1989. Upon his official retirement as 
Director, the Institute changed its name 
to the Gurdon Institute, in his honor. 
Throughout all of these years Gurdon 
stayed at the bench and continued to 
work on the overall changes that occur lsevier Inc.when nuclei are injected into eggs or 
oocytes. Recent work from the Gurdon 
lab has shown that nuclei may retain 
“epigenetic memory” of their cell of ori-
gin for many cell divisions after nuclear 
transfer, even while the embryonic gene 
expression program is being activated. 
All of these experiments have tended 
to suggest that the process of nuclear 
reprogramming by the egg is a complex 
one that is often incomplete, involving 
general erasure of chromatin marks and 
gradual reestablishment and replace-
ment of transcription factor hierarchies. 
Despite the years of studying the pro-
cess of nuclear transfer, it is still not pos-
sible to reconstruct the reprogramming 
milieu of the egg cytoplasm in vitro.
From Frogs and Dolly to ES Cells 
and iPS Cells
The first reports of deriving human 
embryonic stem (ES) cells occurred 
soon after the reports of successful 
cloning in mammals, and it was only a 
short step to link the two. Although live 
cloned animals are relatively rare, blas-
tocysts derived by SCNT can be used 
to generate embryonic stem cells in 
mice (Wakayama et al., 2001) (Figure 1). 
Excitement and controversy accompa-
nied the concept of being able to repli-
cate this result with human cells: excite-
ment because of the future prospects 
for personalized stem cell therapy and 
the present opportunities for generating 
disease-specific stem cells to study dis-
ease mechanisms in vitro; controversy 
because of the possible connection to 
human reproductive cloning, the ethical 
issues around oocyte donation, and the 
deliberate creation and destruction of 
human embryos, albeit very early ones. 
However, although primate ES cells 
derived by SCNT have been reported, no 
success with human has been reported 
to date. Even in mouse, the number of 
oocytes needed to generate success-
ful SCNT ES cell lines is large and the 
practical difficulties of garnering human 
oocytes in large numbers have impeded 
any real progress in this area.
All of this changed in 2006, when 
Takahashi and Yamanaka published 
their first paper showing that it was pos-
sible to transform mouse tail fibroblasts 
into cells with many of the properties of 
mouse ES cells, by simple expression 
of four transcription factors: 
Oct4, Sox2, c-Myc, and Klf4 
(Takahashi and Yamanaka, 
2006) (Figure 1). These initial 
iPS cells were not completely 
identical to ES cells and their 
ability to contribute to tissues 
in chimeras was limited, with 
no germline transmission. 
And the efficiency of produc-
tion was very low. However, 
no one before had come even 
close to this kind of dramatic 
direct reversal of differen-
tiation. Rapidly thereafter, 
Yamanaka’s lab and others 
improved the selection pro-
cess for generating iPS cells 
and were able to generate 
cells that could transmit the 
iPS cell genotype into the 
next generation (Okita et al., 
2007; Wernig et al., 2007). 
Continued improvements in 
mouse iPS cell technology 
have recently led to the gen-
eration of viable mice entirely 
composed of iPS cells by the 
tetraploid complementation 
approach, the final test of iPS 
cell pluripotency.
Although generation of 
mouse iPS cells caused a 
major stir in the research 
community, it was not until 
Yamanaka’s lab and James 
Thomson’s lab separately 
reported success in repro-
gramming adult human skin 
cells to pluripotency that the 
world at large took notice. 
Yamanaka’s lab used the 
same set of transcription factors as 
used in mice (Takahashi et al., 2007), 
whereas Thomson replaced c-MYC 
and KLF4 with LIN28 and NANOG (Yu 
et al., 2007). These human iPS cells 
were pluripotent as judged by in vitro 
differentiation, teratoma formation, 
gene expression, and epigenetic pro-
files, suggesting that the goal of mak-
ing patient-specific stem cells could be 
achieved without resorting to nuclear 
transfer. Right-to-life groups were quick 
to suggest that human iPS cell technol-
ogy made all human ES cell research 
unnecessary, an assertion that was 
rapidly countered by Yamanaka him-
self, who pointed out that human ES 
cells are still the established standard 
against which to measure progress in 
the development of iPS cell method-
ologies.
So what was the path that led 
Yamanaka to his discovery and why was 
it unique? Shinya Yamanaka began his 
career in medical school in Kobe, Japan, 
but found that scientific discovery was 
more to his liking than orthopedic medi-
cine. While working on liver cancer in 
transgenic mice as a post-doc in San 
Francisco, he discovered a gene, Nat1, 
which is important for early development 
and the differentiation of ES cells. That 
began his fascination with the 
genetic network of the pluri-
potent state of ES cells and 
how it is maintained. Return-
ing to Japan, he undertook an 
in silico profiling of ES cells 
versus their differentiated 
progeny, which identified a 
set of highly enriched genes 
in ES cells. These included 
a number of genes encoding 
known and new transcription 
factors. One of these genes 
was Nanog, which both he and 
Austin Smith’s lab showed to 
be a key player in the mainte-
nance of the pluripotent state 
(Chambers et al., 2003; Mit-
sui et al., 2003). Other genes 
included Oct4, Klf4, and Eras, 
all of which have been shown 
individually to be necessary 
for pluripotency but not suf-
ficient on their own to induce 
pluripotency when ectopically 
expressed. What Yamanaka 
did then was simple in ret-
rospect; he argued that to 
convert adult cells all the way 
back to pluripotency might 
require a combination of fac-
tors rather than a single mas-
ter gene. He made a library of 
24 ES cell-enriched factors in 
retroviral vectors and infected 
fibroblasts expressing a 
selectable marker gene under 
the control of one of the ES-
cell-specific genes, Fbx15. 
Selecting these infected 
fibroblasts under ES cell 
culture conditions led to the 
appearance of colonies of ES-like cells 
over a period of time. Through a series 
of permutations and deletions of the 24 
factors, he was able to bring the number 
of necessary genes down to the four so-
called Yamanaka factors (Takahashi and 
Yamanaka, 2006). Careful experimental 
design and a lot of hard work clearly 
paid off!
Following his original experiments, 
there has been a huge explosion in iPS 
cell research, with Yamanaka still in the 
vanguard. Yamanaka has shown that iPS 
cells can be generated without the poten-
tially oncogenic c-Myc (Nakagawa et al., 
2008), that they can be generated from 
Figure 1. Generating Reprogrammed Pluripotent Stem Cells
There are two routes to generate personalized or patient-specific pluripotent 
stem cells. (Left) Nuclear transfer reprogramming involves injection of the 
nucleus of an adult cell into an enucleated oocyte. After a few days of devel-
opment to the blastocyst stage, embryonic stem (ES) cells can be generated 
from any resulting viable blastocysts. (Right) During induced pluripotency, the 
adult cell is directly reprogrammed to pluripotency by transfection of a set of 
genes encoding key transcription factors, followed by careful selection and 
isolation of ES cell-like induced pluripotent stem (iPS) cells over a period of 
2–3 weeks. Both approaches have proved feasible in mice. In humans, no 
nuclear transfer-derived stem cells have yet been reported; however, there are 
now numerous human iPS cells from normal and disease-bearing individuals 
available for study.Cell 138, September 18, 2009 ©2009 Elsevier Inc. 1049
gastric epithelial cells and hepatocytes 
(Aoi et al., 2008), and that it is possible 
to generate iPS cells at low efficiency by 
repeated transient transfection with a 
polycistronic plasmid containing all four 
factors (Okita et al., 2008). He has also 
become the voice for iPS cell research 
in Japan, now heading the Center for iPS 
Cell Research and Application (CiRA) 
at Kyoto University and also holding a 
cross-appointment at the Gladstone 
Institute.
Despite the huge popularity and profile 
of iPS cell research, there are still many 
uncertainties and unanswered questions 
before human iPS cells could be used for 
any direct therapeutic applications. Con-
cern about possible insertional mutagen-
esis and oncogenic activation by retroviral 
integrations has led to a variety of efforts 
to achieve reprogramming without viral 
integration, including the use of transpo-
son vectors that can be later excised from 
the genome, or replacement of the trans-
genes with small molecules or proteins. 
A more overriding concern, however, 
remains, and that is whether iPS cells 
may themselves be predisposed toward 
tumor formation. The inclusion of the pro-
tooncogene c-Myc in the original factor 
mix clearly enhanced the efficiency of 
reprogramming, but in the original mouse 
experiments, Yamanaka reported tumor 
formation in the chimeras generated from 
the iPS cells. Successful reprogramming 
can be achieved without c-Myc, but the 
efficiency is lowered. A series of recent 
reports from Yamanaka and others has 
shown that inactivation of the Ink4a/Arf-
p53 tumor suppressor pathway, even 
transiently, dramatically increases the 
efficiency of reprogramming. This path-
way acts as a major antiproliferative and 
hence antitumorigenic pathway in mam-
malian cells, suggesting a clear relation-
ship between induced pluripotency and 
tumorigenesis. These studies underscore 
how little we still really understand about 
the reprogramming process and certainly 1050 Cell 138, September 18, 2009 ©2009 Esuggest that safe therapeutic use of these 
cells will require more knowledge than we 
have today.
However, the direct use of iPS cells for 
stem cell-based therapy is not the major 
reason for the excitement over this dis-
covery. Generation of human iPS cells 
immediately opened up the possibility 
of efficiently making disease-specific 
stem cells from the cells of individuals 
with a wide range of disorders. Biobank-
ing facilities for iPS cell lines are being 
established in a number of centers, and 
whole new programs of research into dis-
ease mechanisms, drug toxicology, and 
drug development are being fostered 
by the availability of these cells. The 
award of the Lasker prize to Yamanaka 
so soon after the discovery of iPS cells 
attests to the immense future potential of 
this approach to explore human biology 
and to treat human disease. But it also 
reflects the impact his discovery has had 
on the whole concept of the relative irre-
versibility of developmental pathways. If 
adult cells can be sent all the way back to 
pluripotency with just four transcription 
factors, why not redirect adult cells to 
therapeutically important cell types with-
out going through the pluripotency step? 
And preferably do it in vivo to promote 
endogenous repair. A first step in this 
direction was the recent report of redi-
recting exocrine pancreas cells to endo-
crine cells by adenoviral transduction of 
three transcription factors in the living 
animal (Zhou et al., 2008). It is a logical 
progression from Gurdon’s first discov-
ery—that an adult nucleus can retain 
totipotency after nuclear transfer—to the 
apparently unlimited future of directed 
reprogramming. Continued study of the 
mechanism of nuclear reprogramming 
by nuclear transfer should continue to 
inform and improve our ability to directly 
reprogram cell fate in adult cells.
Elements of Yamanaka’s success 
echo those of John Gurdon’s: focus on 
clear and simple questions and design lsevier Inc.simple and elegant experiments to 
address them. The Lasker award to 
both celebrates great science with great 
future impact on our understanding and 
treatment of human disease.
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